Neutrophil gelatinase-associated lipocalin, macrophage inhibitory cytokine 1, and carbohydrate antigen 19-9 in pancreatic juice: Pathobiologic implications in diagnosing benign and malignant disease of the pancreas

Pancreas

Volumn 42, Issue 3, 2013, Pages 494-501

  Kaur, Sukhwinder ^a   Baine, Michael J ^b   Guha, Sushovan ^c   Ochi, Nobuo ^c   Chakraborty, Subhankar ^a   Mallya, Kavita ^a   Thomas, Colleen ^d   Crook, Julia ^d   Wallace, Michael B ^d   Woodward, Timothy A ^d   Jain, Maneesh ^a   Singh, Shailender ^b   Sasson, Aaron R ^a   Skinner, Verna ^d   Raimondo, Massimo ^d   Batra, Surinder K ^a,b  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d MAYO CLINIC   (United States)

Author keywords

CA19 9; MIC 1; NGAL; Pancreatic disease; Pancreatic juice

Indexed keywords

CA 19-9 ANTIGEN; GROWTH DIFFERENTIATION FACTOR 15; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; SECRETIN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CHRONIC PANCREATITIS; COMPARATIVE STUDY; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC PATIENT; ENDOSCOPIC ULTRASOUND GUIDED FINE NEEDLE BIOPSY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PANCREAS CANCER; PANCREAS JUICE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RADIOIMMUNOASSAY;

ACUTE-PHASE PROTEINS; AGED; BIOLOGICAL MARKERS; CA-19-9 ANTIGEN; DIABETES MELLITUS, TYPE 2; DIAGNOSIS, DIFFERENTIAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GROWTH DIFFERENTIATION FACTOR 15; HUMANS; LIPOCALINS; MALE; MIDDLE AGED; PANCREAS; PANCREATIC JUICE; PANCREATIC NEOPLASMS; PANCREATITIS, CHRONIC; PROSPECTIVE STUDIES; PROTO-ONCOGENE PROTEINS; RADIOIMMUNOASSAY; SENSITIVITY AND SPECIFICITY;

EID: 84884212819     PISSN: 08853177     EISSN: 15364828     Source Type: Journal    
DOI: 10.1097/MPA.0b013e31826a8597     Document Type: Article

References (32)

1. American Cancer Society. Cancer Facts and Figures 2010. Atlanta, GA: American Cancer Society; 2010.
2. Centers for Disease Control and Prevention. National Diabetes Fact Sheet: National Estimates and General Information on Diabetes and Prediabetes In the United States, 2011. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention; 2011.
3. Chakraborty S, Kaur S, Muddana V, et al. Elevated serum neutrophil gelatinase-associated lipocalin is an early predictor of severity and outcome in acute pancreatitis. Am J Gastroenterol. 2010;105:2050-2059.
4. Chakraborty S, Baine MJ, Sasson AR, et al. Current status of molecular markers for early detection of sporadic pancreatic cancer. Biochim Biophys Acta. 2011;1815:44-64.
5. Tumour markers in gastrointestinal cancersYEGTM recommendations. European Group on TumourMarkers. Anticancer Res. 1999;19:2811-2815.
6. DiMagno EP, Reber HA, Tempero MA. AGA technical review on the epidemiology, diagnosis, and treatment of pancreatic ductal adenocarcinoma. American Gastroenterological Association. Gastroenterology. 1999;117:1464-1484.
7. Goggins M. Molecular markers of early pancreatic cancer. J Clin Oncol. 2005;23:4524-4531.
8. Koopmann J, Buckhaults P, Brown DA, et al. Serum macrophage inhibitory cytokine 1 as a marker of pancreatic and other periampullary cancers. Clin Cancer Res. 2004;10:2386-2392.
9. Moniaux N, Chakraborty S, Yalniz M, et al. Early diagnosis of pancreatic cancer: Neutrophil gelatinase-associated lipocalin as a marker of pancreatic intraepithelial neoplasia. Br J Cancer. 2008;98:1540-1547.
10. Ni XG, Bai XF, Mao YL, et al. The clinical value of serum CEA CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer. Eur J Surg Oncol. 2005;31:164-169.
11. Pleskow DK, Berger HJ, Gyves J, et al. Evaluation of a serologic marker CA19-9, in the diagnosis of pancreatic cancer. Ann Intern Med. 1989;110:704-709.
12. Steinberg W. The clinical utility of the CA 19-9 tumor-associated antigen. Am J Gastroenterol. 1990;85:350-355.
13. Welsh JB, Sapinoso LM, Kern SG, et al. Large-scale delineation of secreted protein biomarkers overexpressed in cancer tissue and serum. Proc Natl Acad Sci U S A. 2003;100:3410-3415.
14. Bauer M, Eickhoff JC, Gould MN, et al. Neutrophil gelatinase-associated lipocalin (NGAL) is a predictor of poor prognosis in human primary breast cancer. Breast Cancer Res Treat. 2008;108:389-397.
15. Nielsen BS, Borregaard N, Bundgaard JR, et al. Induction of NGAL synthesis in epithelial cells of human colorectal neoplasia and inflammatory bowel diseases. Gut. 1996;38:414-420.
16. Lim R, Ahmed N, Borregaard N, et al. Neutrophil gelatinase-associated lipocalin (NGAL) an early-screening biomarker for ovarian cancer: NGAL is associated with epidermal growth factor-induced epithelio-mesenchymal transition. Int J Cancer. 2007;120:2426-2434.
17. Monier F, Surla A, Guillot M, et al. Gelatinase isoforms in urine from bladder cancer patients. Clin Chim Acta. 2000;299:11-23.
18. Bootcov MR, Bauskin AR, Valenzuela SM, et al. MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-beta superfamily. Proc Natl Acad Sci U S A. 1997;94:11514-11519.
19. Del Villano BC, Brennan S, Brock P, et al. Radioimmunometric assay for a monoclonal antibody-defined tumor marker, CA 19-9. Clin Chem. 1983;29:549-552.
20. Pannala R, Basu A, Petersen GM, et al. New-onset diabetes: A potential clue to the early diagnosis of pancreatic cancer. Lancet Oncol. 2009;10:88-95.
21. Buxbaum JL, Eloubeidi MA. Molecular and clinical markers of pancreas cancer. JOP. 2010;11:536-544.
22. Furuya N, Kawa S, Hasebe O, et al. Comparative study of CA242 and CA19-9 in chronic pancreatitis. Br J Cancer. 1996;73:372-376.
23. Talar-Wojnarowska R, Gasiorowska A, Olakowski M, et al. Clinical value of serum neopterin, tissue polypeptide-specific antigen and CA19-9 levels in differential diagnosis between pancreatic cancer and chronic pancreatitis. Pancreatology. 2010;10:689-694.
24. Rosty C, Christa L, Kuzdzal S, et al. Identification of hepatocarcinoma-intestine-pancreas/pancreatitis-associated protein I as a biomarker for pancreatic ductal adenocarcinoma by protein biochip technology. Cancer Res. 2002;62:1868-1875.
25. Chen R, Pan S, Duan X, et al. Elevated level of anterior gradient-2 in pancreatic juice from patients with pre-malignant pancreatic neoplasia. Mol Cancer. 2010;9:149.
26. Rogers CD, Fukushima N, Sato N, et al. Differentiating pancreatic lesions by microarray and QPCR analysis of pancreatic juice RNAs. Cancer Biol Ther. 2006;5:1383-1389.
27. Nakashima A, Murakami Y, Uemura K, et al. Usefulness of human telomerase reverse transcriptase in pancreatic juice as a biomarker of pancreatic malignancy. Pancreas. 2009;38:527-533.
28. Zhou L, Lu Z, Yang A, et al. Comparative proteomic analysis of human pancreatic juice: Methodological study. Proteomics. 2007;7:1345-1355.
29. Yan L, Tonack S, Smith R, et al. Confounding effect of obstructive jaundice in the interpretation of proteomic plasma profiling data for pancreatic cancer. J Proteome Res. 2009;8:142-148.
30. Nishida K, Tasaki N, Miyagawa H, et al. Estimation of carbohydrate antigen (CA) 19-9 levels in pure pancreatic juice of patients with pancreatic cancer. Am J Gastroenterol. 1988;83:126-129.
31. Wakabayashi T, Sawabu N, Takemori Y, et al. Diagnostic significance of cancer-associated carbohydrate antigen (CA19-9) concentrations in pancreatic juice: Analysis in pure pancreatic juice collected by endoscopic aspiration and immunohistochemical study in chronic pancreatitis. Pancreas. 1993;8:151-159.
32. Dostalova I, Roubicek T, Bartlova M, et al. Increased serum concentrations of macrophage inhibitory cytokine-1 in patients with obesity and type 2 diabetes mellitus: The influence of very low calorie diet. Eur J Endocrinol. 2009;161:397-404.